A Model For Improved Cost Of Goods In Cell Process Therapy

By Matthieu Egloff, ATMI and Guillaume DeViron, Norived

This white paper presents a cost model using bottom-up simulation. The article includes supporting evidence from studies of migrating translation research into clinical scale manufacturing. Evidence is presented for comparison of a high yield performance platform to the emerging cell culture bioreactor platform. This comparison is used to determine true cost of goods. (COGS)